RevMAb Biosciences, It is a biotechnology company focused on the development of recombinant monoclonal antibodies. The key element differentiating the company's approach is its technology, which relies on developing antibodies from antigen-specific B cells without the need for traditional cell fusion and hybridoma generation processes. 

In RevMAb technology, B cells obtained from immunized animals are directly screened to identify cells specific to the target antigen. Then, the relevant antibody genes are cloned, and recombinant antibodies are produced via mammalian cell expression systems. This approach enables the development of recombinant monoclonal antibodies with high specificity and for different research objectives. 

RevMAb's product portfolio includes rabbit and goat monoclonal antibodies for research and pathology applications, as well as histone modifications, variant-specific targets, IHC markers, and products for various research applications. The company also offers services such as custom antibody development, assay development, and antibody engineering.